Spec­trum yanks mar­ket­ing ap­pli­ca­tion for Neu­las­ta ri­val af­ter FDA de­mands more da­ta

Months af­ter Spec­trum Phar­ma­ceu­ti­cals in­formed in­vestors that the FDA had de­nied its lung can­cer drug pozi­o­tinib the break­through ther­a­py sta­tus tag, the drug­mak­er said it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.